

LAURA CONTI

Work address: Dept. of Molecular Biotechnology and Health Sciences, University of Turin, Via Nizza 52, Torino, Italy. **Phone:** +39 011 670 6458. **E-mail:** laura.conti@unito.it

Education

2003-2007: PhD in Immunology and Cell Biology, University of Turin, Dept. of Clinical and Biological Sciences. "Modulation of IFNs/STAT1 signaling pathways in tumors and autoimmunity". PI Prof F Novelli.

1998-2003: Master's degree in Medical Biotechnology, University of Turin, 110/110 *maxima cum laude*. Experimental thesis with printing honor and mention: "Role of Iron in the regulation of IFN- α R expression on human lymphocytes". Advisor Prof M Giovarelli, PI Prof F Novelli. **1993-1998:** Liceo Scientifico E. Majorana, Turin. 60/60.

Research experience

From 23/12/2022 to present. Associate Professor of Immunology – General Pathology, University of Turin, Dept of Molecular Biotechnology and Health Science.

From 23/12/2019 to 22/12/2022. Assistant Professor of Immunology – General Pathology, University of Turin, Dept of Molecular Biotechnology and Health Science.

November 2018. Visiting Scientist at AgilVax Inc., JLABS@TMC, Houston (Texas).

January 2018-December 2019. Research Fellow, Dissecting the role of xCT in tumor cells and the immune system, University of Turin, Dept of Molecular Biotechnology and Health Science.

January 2016-December 2017. Fellow of the Fondazione Umberto Veronesi. Fighting breast cancer stem cells through the immune-targeting of the xCT cystine/glutamate antiporter. University of Turin, Dept of Molecular Biotechnology and Health Science. PI Prof F Cavallo.

May-December 2015. Fellow of the Fondazione Ricerca Molinette Onlus. Evaluation of anti-xCT vaccine immunogenicity. University of Turin, Dept of Molecular Biotechnology and Health Science. PI Prof F Cavallo.

May 2014-May 2015. Fellow of the Fondazione Umberto Veronesi. Identification of Cancer Stem Cell Oncoantigens For The Immune-Targeting Of Triple Negative Breast Cancer. University of Turin, Dept of Molecular Biotechnology and Health Science. PI Prof F Cavallo.

June 2013. Visiting Scientist at Transgene SA, Illkirch Graffenstaden Cedex, France.

2009-2014. Post-doctoral Fellow, University of Turin, Dept. of Molecular Biotechnology and Health Science. PI Prof G Forni. Identification of oncoantigens expressed in breast cancer stem cells. Immunotherapy of breast cancer. *In vivo* optical imaging of tumors.

2007- 2009. Bracco Imaging SpA. Fellowship "Synthesis of targeting vectors", Colletterto Giacosa (TO). PI Dr F Maisano and Prof G Forni. *In vivo* optical imaging of tumors and inflammation. Characterization of breast cancer stem cell markers.

2003- 2007. PhD in Immunology and Cell Biology, Dept.of Clinical and Biological Sciences, University of Turin. Study of IFNs signaling in neoplastic T lymphocytes and in Th17 cells in Multiple Sclerosis. PI Prof F Novelli.

2000- 2003. Trainee at the Laboratory of Tumor Immunology, CERMS, University of Turin.

Awards

2016: NIBIT award for the best abstract of the "Cancer Bio-Immunotherapy" Meeting.

2014: Fellowship of the Fondazione Chianello for contributions in oncology.

2011: Prize for the best abstract, 1st Ascoli Piceno Conference on Gene vaccination in cancer.

2007: Travel grant for the 5th National Conference SIICA, Trieste, Italy.

2004: University of Turin award for the Best Biotechnology Thesis, a.a. 2002/2003.

Grants:

2022-2027: "Role of Toll-like receptor 2 in tumor cell-autonomous and microbiota-driven chemoresistance in breast cancer" Investigator Grant AIRC 2021 - ID 25766.

2022-2023: "Development of a novel combined immunotherapy able to activate the immune response through STING agonists for the treatment of breast cancer". Fondazione CRT, RF 2021.1774.

2021-2022: "Targeting TLR2 and its cross-talk with the cystine/glutamate antiporter xCT as a new combined therapy for breast cancer", University of Turin.

2021-2022: "BiotecXFuture", CIRDA, University of Turin.

2020-2021: "Toll-like receptor2 (TLR2) is a new target for breast cancer therapy" University of Turin.

2016-2019: Italian Ministry of Health, Bando RF-2013-02354892, "Pancreatic cancer therapy based on combination of DNA vaccination and PI3Kgamma inhibition". Unit PI (Coordinator: Prof F Novelli) [Patents:](#)

Composition and Methods for immunotargeting xCT peptides (US Patent num 11,040,223 B2, 22nd June 2022). Role: INVENTOR.

Publications:

ORCID ID: 0000-0003-1780-098X

Scopus Author ID: 16041417500

Web of Science Researcher ID: A-9005-2017

1. C Curcio, G Mucciolo, C Roux, S Brugiapaglia, A Scagliotti, G Guadagnin, L Conti, D Longo, D Grosso, MG Papotti, E Hirsch, P Cappello, JA Varner, F Novelli. PI3Kγ inhibition combined with DNA vaccination unleashes a B-cell-dependent antitumor immunity that hampers pancreatic cancer. *Journal of experimental & clinical cancer research* : CR, 2024, 43(1), pp. 157.
2. I Garzia, L Nocchi, L Avalor, F Troise, G Leoni, L Seclì, L Antonucci, G Cotugno, S Allocca, G Romano, L Conti, C Caiazza, M Mallardo, V Poli, E Scarselli, AM D'Alise. Tumor burden dictates the neoantigens' vaccine features required for effective tumor rejection. *Cancer Immunol Research* 2024, 12(4):440-452.
3. Cossu C, Di Lorenzo A, Fiorilla I, Todesco AM, Audrito V, Conti L. The Role of the Toll-like Receptor 2 and the cGAS-STING Pathways in Breast Cancer: Friends or Foes? *Int. J. Mol. Sci.* 2024, 25(1), 456.
4. Di Gregorio E, Papi C, Conti L, Di Lorenzo A, Cavallari E, Salvatore M, Cavaliere C, Ferrauto G, Aime S. A Magnetic Resonance Imaging-Chemical Exchange Saturation Transfer (MRI-CEST) Method for the Detection of Water Cycling across Cellular Membranes. *Angew Chem Int Ed Engl.* 2023:e202313485.
5. Mina Erica, Wyart E, Sartori R, Angelino E, Zaggia I, Rausch V, Maldotti M, Pagani A, Hsu M, Friziero, A, Sperti C, Menga A, Graziani A, Hirsch E, Oliviero S, Sandri M, Conti L, Kautz L, Silvestri L, Porporato PE. K506 bypasses the effect of erythroferrone in cancer cachexia skeletal muscle atrophy. *Cell Reports Medicine* 4(12), 101306.
6. R Ruiu, C Cossu, A Iacoviello, L Conti, E Bolli, L Ponzzone, J Magri, A Rumandla, E Calautti, F Cavallo. Cystine/glutamate antiporter xCT deficiency reduces metastasis without impairing immune system function in breast cancer mouse models. *Journal of Experimental & Clinical Cancer Research* 2023, 42(1), 254.

7. SC Park, L Conti, V Franceschi, B Oh, MS Yang, Gaeul Ham, A Di Lorenzo, E Bolli, Fa Cavallo, B Kim, G Donofrio. Assessment of BoHV-4-based vector vaccine intranasally administered in a hamster challenge model of lung disease. *Frontiers in Immunology* 2023. DOI: 10.3389/fimmu.2023.1197649 (Co-first)
8. Levra Levron C, Watanabe M, Proserpio V, Piacenti G, Lauria A, Kaltenbach S, Tamburrini A, Nohara T, Anselmi F, Duval C, Elettrico L, Donna D, Conti L, Baev D, Natsuga K, Hagai T, Oliviero S, Donati G. Tissue memory relies on stem cell priming in distal undamaged areas. *Nature Cell Biology* 2023, in press.
9. V Salemme, M Vedelago, A Sarcinella, F Moietta, A Piccolantonio, E Moiso, G Centonze, M Manco, A Guala, A Lamolinara, C Angelini, A Morellato, D Natalini, R Calogero, D Incarnato, S Oliviero, L Conti, M Iezzi, D Tosoni, G Bertalot, S Freddi, F Tucci, F De Sanctis, C Frusteri, S Ugel, V Bronte, F Cavallo, P Provero, M Gai, D Taverna, E Turco, S Pece, and P Defilippi. p140Cap inhibits β -Catenin in the breast cancer stem cell compartment instructing a protective anti-tumor immune response. *Nature Communications* 2023, in press.
10. Yaghobinejad M, Cavallo F, Conti L, Quaglino E. The 21st International Conference on Progress in Vaccination against Cancer (PIVAC-22), September 26-28, 2022, Turin, Italy. *Frontiers in bioscience (Landmark edition)*, 2022, 27(12), pp. 338.
11. Capozza M, Stefania R, Dinatale V, Bitonto V, Conti L, Grange C, Skovronova, R. Terreno, E. A Novel PSMA-Targeted Probe for NIRF-Guided Surgery and Photodynamic Therapy: Synthesis and Preclinical Validation. *International Journal of Molecular Sciences*, 2022, 23(21), 12878
12. Di Gregorio E, Romiti C, Di Lorenzo A, Cavallo F, Ferrauto G, Conti L. RGD_PLGA Nanoparticles with Docetaxel: A Route for Improving Drug Efficiency and Reducing Toxicity in Breast Cancer Treatment. *Cancers (Basel)*. 2022 Dec 20;15(1):8. doi: 10.3390/cancers15010008.
13. Barutello G, Di Lorenzo A, Gasparetto A, Galiuzzi C, Bolli E, Conti L, Cavallo F. Immunotherapy against the Cystine/Glutamate Antiporter xCT Improves the Efficacy of APR-246 in Preclinical Breast Cancer Models. *Biomedicines*. 2022 Nov 8;10(11):2843. 10.3390/biomedicines10112843 (Co-last).
14. Wang J, Lamolinara A, Conti L, Giangrossi M, Cui L, Morelli MB, Amantini C, Falconi M, Bartolacci C, Andreani C, Orlando F, Provinciali M, Del Pizzo FD, Russo F, Belletti B, Riccardo F, Bolli E, Quaglino E, Cavallo F, Amici A, Iezzi M, Marchini C. HER2-Displaying M13 Bacteriophages induce Therapeutic Immunity against Breast Cancer. *Cancers (Basel)*. 2022 Aug 22;14(16):4054.
15. Di Lorenzo A, Bolli E, Ruiu R, Ferrauto G, Di Gregorio E, Avalle L, Savino A, Poggio P, Merighi IF, Riccardo F, Brancaccio M, Quaglino E, Cavallo F, Conti L. Toll-like receptor 2 promotes breast cancer progression and resistance to chemotherapy. *Oncoimmunology*. 2022 Jun 15;11(1):2086752.
16. Federica Riccardo, Lidia Tarone, Mariateresa Camerino, Davide Giacobino, Selina Iussich, Giuseppina Barutello, Maddalena Arigoni, Laura Conti, Elisabetta Bolli, Elena Quaglino, Irene Fiore Merighi, Emanuela Morello, Alfredo Dentini, Soldano Ferrone, Paolo Buracco, Federica Cavallo. Antigen mimicry as an effective strategy to induce CSPG4-targeted immunity in dogs with oral melanoma: a veterinary trial. *J Immunotherapy of Cancer*, 2022, 10(5), e004007.
17. Roberto Ruiu, Antonino Di Lorenzo, Federica Cavallo, Laura Conti. Are Cancer Stem Cells a suitable target for breast cancer immunotherapy? *Frontiers in Oncology* 2022, Vol. 12. 10.3389/fonc.2022.877384
18. Macagno M, Bandini S, Bolli E, Bello A, Riccardo F, Barutello G, Merighi IF, Forni G, Lamolinara A, Del Pizzo F, Iezzi M, Cavallo F, Conti L, Quaglino E. Role of ADCC, CDC, and CDCC in Vaccine-Mediated Protection against Her2 Mammary Carcinogenesis. *Biomedicines*, 2022, 10(2), 230. (Corresponding author).
19. Proserpio V, Conti L, Oliviero S. Flow cytometry Single cells for Beginners: Hints and Tips for Approaching the Very First Single-Cell Single cells Technique. *Methods Molecular Biology*, Vol. 2386, 2022.10.1007/978-1-0716-1771-7. (all the authors contributed equally).

20. L Seclì, L Avalle, Pietro Poggio, G Fragale, C Cannata, L Conti, A Iannucci, G Carrà, C Rubinetto, B Miniscalco, E Hirsch, V Poli, A Morotti, M De Andrea, E Turco, F Cavallo, F Fusella, M Brancaccio. Targeting the extracellular HSP90 co-chaperone Morgana inhibits cancer cell migration and promotes anti-cancer immunity. *Cancer Res* 2021, 5;81(18):4794-4807.
21. Ruiu, R.; Barutello, G.; Arigoni, M.; Riccardo, F.; Conti, L.; Peppino, G.; Annaratone, L.; Marchiò, C.; Mengozzi, G.; Calogero, R.A.; Cavallo, F; Quaglino, E. Identification of TENM4 as a Novel Cancer Stem Cell-Associated Molecule and Potential Target in Triple Negative Breast Cancer. *Cancers* 2021, 13(4), 894.
22. V Salemme, G Centonze, F Cavallo, P Defilippi, L Conti. The crosstalk between tumor cells and the immune microenvironment in breast cancer: implications for immunotherapy. *Frontiers in Oncology* 2021, 11:610303.
23. J Magri, A Gasparetto, L Conti, E Calautti, C Cossu, R Ruiu, G Barutello, Federica Cavallo. The tumor-associated antigen xCT and mutant-p53 as molecular targets for new combinatorial antitumor strategies. *Cells* 2021, 10(1), 108.
24. A Anemone, L Consolino, L Conti, P Irrera, M Hsu, D Villano, W Dastrù, P Porporato, F Cavallo, D Longo. Tumour acidosis evaluated in vivo by MRI-CEST pH imaging reveals breast cancer metastatic potential. *British Journal of Cancer* 2021, 124(1):207-216.
25. A Di Lorenzo, E Bolli, L Tarone, F Cavallo, L Conti. Toll-Like Receptor 2 at the Crossroad between Cancer Cells, the Immune System, and the Microbiota. *Int. J. Mol. Sci.* 2020, 21(24), 9418.
26. Quaglino E, Cavallo F, Conti L. Cancer stem cell antigens as targets for new combined anti-cancer therapies. *The International Journal of Biochemistry & Cell Biology* 2020, 105861.
27. L Conti, E Bolli, A Di Lorenzo, V Franceschi, F Macchi, F Riccardo, R Ruiu, L Russo; E Quaglino, G Donofrio, F Cavallo. Immunotargeting of the xCT cystine/glutamate antiporter potentiates the efficacy of Her2-targeted immunotherapies in breast cancer. *Cancer Immunology Research* 8(8), 1039-1053.
28. V Rolih, J Caldeira, E Bolli, A Salameh, L Conti, G Barutello, F Riccardo, J Magri, A Lamolinara, K Parra, P Valenzuela, G Francia, M Iezzi, F Pericle, F Cavallo. Development of a VLP-based Vaccine Displaying an xCT Extracellular Domain for the Treatment of Metastatic Breast Cancer. *Cancers* 12(6), 1-21, 1492.
29. L Avalle; F Marino; A Camporeale; C Guglielmi; D Viavattene; S Bandini; L Conti; J Cimino; M Forni; C Zanini; A Ghigo; RL Bogorad; F Cavallo; P Provero; V Koteliansky; VPoli. Liver-specific siRNA-mediated Stat3 or C3 knock-down improves the outcome of experimental autoimmune myocarditis. *Molecular Therapy - Methods and Clinical Development* 2020, 18, 62-72.
30. Riccardo F, Barutello G, Petito A, Tarone L, Conti L, Arigoni M, Musiu C, Izzo S, Volante M, Longo DL, Merighi IF, Papotti M, Cavallo F, Quaglino E. Immunization against ROS1 by DNA Electroporation Impairs K-Ras-Driven Lung Adenocarcinomas. *Vaccines* 2020, 8(2), 166.
31. Quaglino E, Conti L, Cavallo F. Breast cancer stem cell antigens as targets for immunotherapy. *Seminars in Immunology* 2020, 47, 101386. (all the authors contributed equally).
32. ES Famulari, V Navarro-Tableros, MB Herrera Sanchez, G Bortolussi, M Gai, L Conti, L Silengo, E Tolosano, C Tetta, AF Muro, G Camussi, S Fagoonee, F Altruda. Human liver stem cells express UGT1A1 and improve phenotype of immunocompromised Crigler Najjar syndrome type I mice. *Scientific Reports* 2020; 10(1): 887.
33. Quirico L, Orso F, Esposito CL, Bertone S, Coppo R, Conti L, Catuogno S, Cavallo F, de Franciscis V, Taverna D. Axl-148b chimeric aptamers inhibit breast cancer and melanoma progression. *International Journal of Biological Sciences* 2020, 16(7), 1238-1251

34. Ruiu R, Tarone L, Rolih V, Barutello G, Bolli E, Riccardo F, Cavallo F, Conti L. Cancer stem cell immunology and immunotherapy: Harnessing the immune system against cancer's source. *Progress in Molecular Biology and Translational Science* 2019; 164: 119-188.
35. Ruiu R, Rolih V, Bolli E, Barutello G, Riccardo F, Quaglino E, Merighi IF, Pericle F, Donofrio G, Cavallo F, Conti L. Fighting breast cancer stem cells through the immune-targeting of the xCT cystine-glutamate antiporter. *Cancer Immunol Immunother* 2019;68(1):131-141.
36. G Donofrio, G Tebaldi, S Lanzardo, R Ruiu, E Bolli, A Ballatore, V Rolih, F Macchi, L Conti*, F Cavallo*. Bovine herpesvirus 4-based vector delivering the full length xCT DNA efficiently protects mice from mammary cancer metastases by targeting cancer stem cells. *Oncoimmunology* 2018, 7:e1494108. (*these authors contributed equally)
37. Witt K, Ligtenberg MA, Conti L, Lanzardo S, Ruiu R, Wallmann T, Tufvesson-Stiller H, Chambers BJ, Rolny C, Lladser A, Lundqvist A, Cavallo F, Kiessling R. Cripto-1 plasmid DNA vaccination targets metastasis and cancer stem cells in murine mammary carcinoma. *Cancer Immunol Res* 2018, Nov;6(11):1417-1425.
38. G Barutello, V Rolih, M Arigoni, L Tarone, L Conti, E Quaglino, P Buracco, F Cavallo, F Riccardo. Strengths and Weaknesses of Pre-Clinical Models for Human Melanoma Treatment: Dawn of Dogs' Revolution for Immunotherapy. *International Journal of Molecular Sciences* 2018, 19:799.
39. E Bolli, JP. O'Rourke, L Conti, S Lanzardo, V Rolih, JM. Christen, G Barutello, M Forni, FPericle, F Cavallo. A Virus-Like-Particle immunotherapy targeting Epitope-Specific anti-xCT expressed on cancer stem cell inhibits the progression of metastatic cancer in vivo. *Oncoimmunology* 2017, 7: e1408746.
40. F Fusella, L Seclì, E Busso, A Krepelova, E Moiso, S Rocca, L Conti, L Annaratone, C Rubinetto, M Mello-Grand, V Singh, G Chiorino, L Silengo, F Altruda, E Turco, A Morotti, S Oliviero, I Castellano, F Cavallo, P Provero, G Tarone, M Brancaccio. The IKK/ NF- κ B signalling pathway requires Morgana to drive breast cancer metastasis. *Nature Communications* 2017, 8:1636.
41. Anemone A, Consolino L, Conti L, Reineri F, Cavallo F, Aime S, Longo DL. In vivo evaluation of tumour acidosis for assessing the early metabolic response and onset of resistance to dichloroacetate by using magnetic resonance pH imaging. *International Journal of Oncology*, 2017, 51:498-506.
42. R Tallerico*, L Conti*, S Lanzardo*, R Sottile, C Garofalo, A Wagner, M Johansson, C Cristiani, K K Kärre, E Carbone, F Cavallo NK cells control breast cancer and related cancer stem cell hematological spread. *Oncoimmunology* 2017, e1284718. (*these authors contributed equally).
43. C Bosia, F Sgrò, L Conti, C Baldassi, D Brusa, F Cavallo, F Di Cunto, E Turco, A Pagnani and R Zecchina. RNAs competing for microRNAs mutually influence their fluctuations in a highly non-linear microRNA-dependent manner in single cells. *Genome Biology* 2017,18:17-30.
44. S Bandini, M Macagno, A Hysi, S Lanzardo, L Conti, A Bello, F Riccardo, R Ruiu, IF Merighi, G Forni, M Iezzi, E Quaglino and F Cavallo. The non inflammatory role of C1q during Her2/neu driven mammary carcinogenesis. *Oncoimmunology* 2016, 5:e1253653.
45. Longo DL, Stefania R, Callari C, De Rose F, Rolle R, Conti L, Consolino L, Arena F, Aime S. Water Soluble Melanin Derivatives for Dynamic Contrast Enhanced Photoacoustic Imaging of Tumor Vasculature and Response to Antiangiogenic Therapy. *Adv Healthc Mater.* 2016, Jan;6. doi: 10.1002/adhm.201600550
46. L Conti, S Lanzardo, R Ruiu, M Cadenazzi, F Cavallo, S Aime, S Geninatti Crich. L- Ferritin targets breast cancer stem cells and delivers therapeutic and imaging agents. *Oncotarget* 2016;7:66713-66727.
47. CL Gigliotti, R Minelli, R Cavalli, S Occhipinti, G Barrera, S Pizzimenti, G Cappellano, E Boggio, L Conti, R Fantozzi, M Giovarelli, F Trotta, U Dianzani, C Dianzani. In Vitro and In Vivo Therapeutic Evaluation of

Camptothecin-Encapsulated β -Cyclodextrin Nanosponges in Prostate Cancer. *Journal of Biomedical Nanotechnology* 2016; 12(1):114-127.

48. S Lanzardo*, L Conti*, R Rooke, R Ruiu, N Accart, E Bolli, M Arigoni, M Macagno, G Barrera, S Pizzimenti, L Aurisicchio, RA Calogero, F Cavallo. Immunotargeting of antigen xCT attenuates stem-like cell behavior and metastatic progression in breast cancer. *Cancer Research* 2016; 7:62-72. (*these authors contributed equally)

49. S Geninatti Crich, M Cadenazzi, S Lanzardo, L Conti, R Ruiu, D Alberti, F Cavallo, JC Cutrin, S Aime. Targeting ferritin receptors for the selective delivery of imaging and therapeutic agents to breast cancer cells. *Nanoscale* 2015; 7:6527-33.

50. M Principe, P Ceruti, NY Shih, M Chattaragada, S Rolla, L Conti, M Bestagno, L Zentilin, SH Yang, P Migliorini, P Cappello, O Burrone, F Novelli. Targeting of surface alpha-Enolase inhibits the invasiveness of pancreatic cancer cells. *Oncotarget* 2015, 10;6:11098-113

51. Fornari C, Beccuti M, Lanzardo S, Conti L, Balbo G, Cavallo F, Calogero RA, Cordero F. A mathematical-biological joint effort to investigate the tumor-initiating ability of cancer stem cells. *Plos One* 2014;9(9):e106193.

52. L Conti, R Ruiu, G Barutello, M Macagno, S Bandini, F Cavallo and S Lanzardo. Microenvironment, oncoantigens and anti-tumor vaccination: lessons learned from BALB-neuT mice. *Biomed Research International*, 2014:534969.

53. M Macagno, S Bandini, L Stramucci, E Quaglino, L Conti, E Balmas, MJ.Smyth, PL Lollini, P Musiani, G Forni, M Iezzi, F Cavallo. Multiple roles of perforin in hampering ErbB2 (HER2/neu) carcinogenesis in transgenic male mice. *J Immunol* 2014, 192:5434-41.

54. C Dianzani, R Minelli, CL Gigliotti, S Occhipinti, M Giovarelli, L Conti, E Boggio, Y Shivakumar, R Pili, R Fantozzi, G Baldanzi, V Malacarne, R Fantozzi, J Yagi, JM Rojo, A Chiocchetti, U Dianzani. B7h triggering inhibits the migration of tumor cell lines. *Journal of Immunology* 2014;15;192:4921-31.

55. Bolli E, Conti L, Riccardo F, Marchini C, Amici A, Cavallo F, Quaglino E. Second Ascoli Piceno Conference on Gene Vaccination in Cancer (GVC), Ascoli Piceno, Italy, October 9th-11th, 2013. *Cancer Immunol Immunotherapy* 2014;63:529-33.

56. L Conti, S Lanzardo, M Arigoni, R Antonazzo, E Radaelli, D Cantarella, RA Calogero, F Cavallo. The non-inflammatory role of High mobility group box 1/Toll-like Receptor 2 axis in the self-renewal of mammary cancer stem cells. *FASEB Journal*, 2013,27:4731-44.

57. R Minelli, S Occhipinti, C L Gigliotti, G Barrera, P Gasco, L Conti, A Chiocchetti, G P Zara, R Fantozzi, M Giovarelli, U Dianzani, C Dianzani. Solid lipid nanoparticles of cholesteryl butyrate inhibit the proliferation of cancer cells in vitro and in vivo models. *British Journal of Pharmacology* 2013, 170:233-44.

58. Conti L, Lanzardo S, Iezzi M, Montone M, Bolli E, Brioschi C, Maiocchi A, Forni G, and Cavallo F. Optical imaging detection of microscopic mammary cancer in ErbB-2 transgenic mice through the DA364 probe binding $\alpha\beta 3$ integrins. *Contrast Media and Molecular Imaging*, 2013;8:350-60.

59. Arigoni M, Barutello G, Riccardo F, Ercole E, Cantarella D, Orso F, Conti L, Lanzardo S, Taverna D, Merighi I, Calogero RA, Cavallo F, Quaglino E. miR-135b coordinates progression of ErbB2-driven mammary carcinomas through suppression of MID1 and MTCH2. *American Journal of Pathology* 2013, 182:2058-70.

60. Cordero F, Beccuti M, Fornari C, Lanzardo S, Conti L, Cavallo F, Balbo G, Calogero RA. Multi-level model for the investigation of oncoantigen-driven vaccination effect. *BMC Bioinformatics*. 2013;14 Suppl 6:S11

61. Conti L, De Palma R, Rolla S, Boselli D, Rodolico G, Kaur S, Silvennoinen O, Niccolai E, Amedei A, Ivaldi F, Clerico M, Contessa G, Uccelli A, Durelli L, Novelli F. Th17 cells in multiple sclerosis express higher levels of JAK2, which increases their surface expression of IFN- γ R2. *Journal of Immunology*, 2012;188:1011-1018
62. Geninatti S, Cutrin JC, Lanzardo S, Conti L, Kalman FK, Szabo I, Lago NR, Iolascon A, and Aime S. Mn-loaded apoferritin: a highly sensitive MRI imaging probe for the detection and characterization of hepatocarcinoma lesions in a transgenic mouse model. *Contrast Media and Molecular Imaging*, 2012;7:281-288.
63. Lanzardo S*, Conti L*, Brioschi C, Bartolomeo MP, Arosio D, Belvisi L, Manzoni L, Maiocchi A, Maisano F, Forni G. A new optical imaging probe targeting α V β 3 integrin in glioblastoma xenografts. *Contrast Media and Molecular Imaging*, 2011;6:449-458 (*these authors contributed equally)
64. Cordero F, Lanzardo S, Arigoni M, Fornari C, Conti L, Balbo G, Cavallo F, Manini D, Calogero RA. Cancer Stem Cell based adjuvant for oncoantigen-driven vaccination. (2011) 2011 ACM Conference on Bioinformatics, Computational Biology and Biomedicine, BCB 2011, p. 564 - 568.
65. Regis G, Icardi L, Conti L, Chiarle R, Piva R, Giovarelli M, Poli V, Novelli F. IL-6 but not IFN-g triggers apoptosis and inhibits in vivo growth of human malignant T cells upon STAT3 silencing. *Leukemia* 2009, 23:2102-2108.
66. Durelli L*, Conti L*, Clerico M, Boselli D, Contessa G, Ripellino P, Ferrero B, Eid P, Novelli F. T Helper 17 Cells Expand in Multiple Sclerosis and are Inhibited by Interferon- β . *Annals of Neurology* 2009,65:499-509 (*these authors contributed equally).
67. Conti L, Regis G, Longo A, Bernabei P, Chiarle R, Giovarelli M, Novelli F. In The Absence Of Igf-1 Signaling, Ifn-g Suppresses Human Malignant T Cell Growth. *Blood* 2007, 109:2496-2504.
68. Regis G, Conti L, Boselli D, Novelli F. Ifngamma2 Trafficking Tunes Ifngamma-Stat1 Signaling In T Lymphocytes. *Trends Immunol.* 2006, 27:96-101.
69. Regis G, Bosticardo M, Conti L, De Angelis S, Boselli D, Tomaino B, Bernabei P, Giovarelli M, Novelli F. Iron Regulates T Lymphocyte Sensitivity To The Ifn-g/Stat1 Signaling Pathway In Vitro And In Vivo. *Blood* 2005, 105:3214-3221.


